The FDA decision on Aerie Pharmaceuticals Inc.’s (AERI) Rocklatan, a once-daily eye drop designed to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension is expected on March 14, 2019.Rocklatan is a fixed-dose combination of Aerie’s Rhopressa, which is currently available in the United States, and widely-prescribed PGA (prostaglandin analog) Latanoprost.If approved by the FDA, Rocklatan will be only US product approved based upon superiority to a prostaglandin.Analysts rate Rocklatan as a potential blockbuster drug.AERI closed Tuesday’s trading at $46.13, up 14.81%.